AMPKβ2 Inhibitors

The category of compounds termed AMPKβ2 Inhibitors encompasses chemicals that indirectly target or influence the activity of the AMPKβ2 subunit by modulating the AMPK complex or related metabolic pathways. These inhibitors do not directly interact with the AMPKβ2 subunit but affect its activity through their impact on the AMPK complex or metabolic signaling pathways.

The primary mechanism through which these inhibitors function involves the modulation of the AMPK complex, which is a central regulator of cellular energy homeostasis. Compounds like Compound C (Dorsomorphin), SBI-0206965, and A-769662 act by inhibiting the AMPK complex, of which AMPKβ2 is a part. This inhibition can lead to altered regulation of metabolic pathways, particularly those related to energy stress responses, glucose uptake, and lipid metabolism. Some of these compounds, such as Metformin and Phenformin, are known primarily for their AMPK-activating effects. However, their complex influence on metabolic pathways can lead to indirect modulation of AMPKβ2 activity. For instance, chronic activation of AMPK by these drugs might lead to feedback inhibition or changes in the expression of AMPK subunits. Other compounds, like Rosiglitazone and statins, exert their effects on AMPKβ2 through broader metabolic pathways, such as those regulated by PPARγ or involved in cholesterol synthesis.